Status:
UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Hepatocellular Carcinoma
Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC. The hypothesis ...
Detailed Description
HCC occurs in the vast majority of cases in the context of cirrhosis. Cirrhosis is considered a pre-cancerous state, which justifies systematic screening for HCC. Screening currently relies on measure...
Eligibility Criteria
Inclusion
- Cirrhotic patients with hepatocellular carcinoma proven by histological examination of a biopsy specimen, eligible for curative treatment (radiofrequency, surgical resection, liver transplantation)
- Patient able to give informed consent
- Patient with Social Security coverage
Exclusion
- Secondary liver tumors
- Non hepatocellular carcinoma primary liver tumor
- Hepatocellular carcinoma without cirrhosis
- Patients with hepatocellular carcinoma and cirrhosis not eligible for curative treatment
- Prisoners
- Adults under guardianship or curatorship
- Pregnancy
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01492127
Start Date
December 1 2011
End Date
March 1 2016
Last Update
April 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Montpellier
Montpellier, France, 34295